2-benzyloxy-6-methoxy-benzaldehyde | 61227-36-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-benzyloxy-6-methoxy-benzaldehyde
• 英文别名: 2-benzyloxy-6-methoxybenzaldehyde；2-methoxy-6-(phenylmethoxy)benzaldehyde；2-Benzyloxy-6-methoxybenzaldehyd；2-methoxy-6-phenylmethoxybenzaldehyde
• CAS: 61227-36-9
• 化学式: C₁₅H₁₄O₃
• 分子量: 242.274
• InChiKey: DSHQZHVVWLPOBE-UHFFFAOYSA-N

物化性质

• 沸点：
  405.7±30.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-benzyloxy-6-methoxy-benzaldehyde 在 chromium(VI) oxide 、 4-二甲氨基吡啶 、 氢氧化钾 、 正丁基锂 、 草酰氯 、 硫酸 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 环己烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 2.33h， 生成 3,5-Bis-benzyloxy-4-(2-benzyloxy-6-methoxy-benzoyl)-benzoic acid (3R,4R)-1-benzyl-3-(4-benzyloxy-benzoylamino)-azepan-4-yl ester
  参考文献：
  名称：

  Synthesis and Protein Kinase Inhibitory Activity of Balanol Analogues with Modified Benzophenone Subunits

  摘要：

  A series of analogues of the protein kinase C (PKC) inhibitory natural product balanol which bear modified benzophenone subunits are described. The analogues were designed with the goal of uncovering structure - activity features that could be used in the development of PKC inhibitors with a reduced polar character compared to balanol itself. The results of these studies suggest that most of the benzophenone features found in the natural product are important for obtaining potent PKC inhibitory compounds. However, several modifications were found to lead to selective inhibitors of the related enzyme protein kinase A (PKA), and several specific modifications to the polar structural elements of the benzophenone were found to provide potent PKC inhibitors. In particular, it was found that replacement of the benzophenone carboxylate with bioisosteric equivalents could lead to potent analogues. Further, a tolerance for lipophilic substituents on the terminal benzophenone ring was uncovered. These results are discussed in light of recently available structural information for PKA.

  DOI：

  10.1021/jm020018f
• 作为产物：
  描述：

  2-benzyloxy-6-methoxybenzyl alcohol 在 四丙基高钌酸铵 、 N-甲基吗啉氧化物 作用下， 以 二氯甲烷 为溶剂， 反应 2.05h， 生成 2-benzyloxy-6-methoxy-benzaldehyde
  参考文献：
  名称：

  EP1783110

  摘要：

  公开号：
• 作为试剂：
  描述：

  potassium tert-butylate 、 甲氧基甲基三苯基氯化膦 、 、 2-benzyloxy-6-methoxy-benzaldehyde 在 氮气 、 2-benzyloxy-6-methoxy-benzaldehyde 、 水 、 Brine 、 magnesium sulfate 、 silica gel 、 ethyl acetate n-hexane 、 三苯基膦 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 0.75h， 以to give 1.75 g of 1-benzyloxy-3-methoxy-2-(2-methoxyvinyl)benzene including a little triphenylphosphine的产率得到1-benzyloxy-3-methoxy-2-(2-methoxyvinyl)benzene
  参考文献：
  名称：

  1-(Piperidin-4- Yl)-1H-Indole Derivatives

  摘要：

  本发明提供了一种由式(1)表示的化合物或其药学上可接受的盐，或其水合物（前提是排除所有R4a、R4b和R4c均为氢原子的化合物）：[其中R1表示氢原子，R2表示氢原子，R3表示式：其中R4a、R4b和R4c相同或不同，且每个表示氢原子、C1-6烷基或C1-6烷氧基等。]

  公开号：

  US20080119518A1

文献信息

• [EN] 1,2-AZOLE DERIVATIVES WITH HYPOGLYSEMIC AND HYPOLIPIDEMIC ACTIVITY<br/>[FR] DERIVES 1,2-AZOLE PRESENTANT UNE ACTIVITE HYPOGLYCEMIQUE ET HYPOLIPIDEMIQUE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2003099793A1

  公开（公告）日：2003-12-04

  A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, - O -, - S - and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents -OR4 (R4 is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.

  化合物的结构式（1），其中环A是一个环，可选地具有1到3个取代基；环B是一个1,2-唑环，可能进一步具有1到3个取代基；Xa、Xb和Xc相同或不同，每个都是键，-O-，-S-等；Ya是一个具有1到20个碳原子的二价脂肪烃残基；Yb和Yc相同或不同，每个是键或具有1到20个碳原子的二价脂肪烃残基；环C是一个可能进一步具有1到3个取代基的单环芳香环；R代表-OR4（R4是氢原子或可选择地取代的碳氢基团）等，或其盐或前药，可用作糖尿病的预防或治疗剂等。
• NOVEL OXAZOLIDINONE DERIVIATIVES
  申请人：Aissaoui Hamed

  公开号：US20120101111A1

  公开（公告）日：2012-04-26

  The present invention relates to oxazolidinone derivatives of formula (I) wherein Y, R 3 and R 4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式(I)的噁唑烷酮衍生物，其中Y、R3和R4如描述中所述，以及它们的制备方法，它们的药用盐，以及它们作为药物的用途，包括含有一个或多个式(I)化合物的药物组合物，特别是它们作为促进睡眠的药物受体拮抗剂的用途。
• A Flexible Approach to 6,5-Benzannulated Spiroketals
  作者：Zoe E. Wilson、Jonathan G. Hubert、Margaret A. Brimble

  DOI：10.1002/ejoc.201100345

  日期：2011.7

  A novel route to simple 6,5-benzannulated spiroketal analogues has been developed. A convergent Horner–Wadsworth–Emmons olefination enabled ready assembly of the spiroketal precursors. Use of a benzyl protecting group strategy enabled an efficient one-pot hydrogenation/deprotection/spiroketalisation process to be employed providing a robust method to access a range of substituted aromatic monobenzannulated

  已经开发了一种简单的 6,5-benzannulated spiroketal 类似物的新途径。收敛的 Horner-Wadsworth-Emmons 烯化使螺酮前体的组装变得容易。苄基保护基策略的使用使得能够采用高效的单锅加氢/脱保护/螺缩酮工艺，提供了一种可靠的方法来获得一系列取代的芳香族单苄基化螺缩酮。
• [EN] LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE LACTAME UTILES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2012063207A1

  公开（公告）日：2012-05-18

  The present invention relates to lactam derivatives of formula (I) wherein Y, R1, R2 and R3 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的内酰胺衍生物，其中Y、R1、R2和R3如描述中所述，以及它们的制备方法，其药学上可接受的盐，以及它们作为药物的用途，包括含有一个或多个公式（I）化合物的药物组合物，特别是它们作为促进睡眠的药物受体拮抗剂的用途。
• 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity
  申请人：Maekawa Tsuyoshi

  公开号：US20060148858A1

  公开（公告）日：2006-07-06

  A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, —O—, —S— and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents —OR 4 (R 4 is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.

  化合物的化学式为(1)，其中环A是一个环，可以有1到3个取代基；环B是一个1,2-咪唑环，可以进一步具有1到3个取代基；Xa，Xb和Xc相同或不同，每个都是键，-O-，-S-等；Ya是具有1到20个碳原子的二价脂肪烃残基；Yb和Yc相同或不同，每个都是键或具有1到20个碳原子的二价脂肪烃残基；环C是一个单环芳香环，可以进一步具有1到3个取代基；R代表-OR4（R4是氢原子或可选的取代烃基）等，或其盐或前药，可用作预防或治疗糖尿病等的药物。